Skip to main content
OpenTrials
Completed

NCT Number: NCT03721549

Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model

There is a need for safe, highly infectious Norovirus inocula for use in Norovirus vaccine-challenge studies to assess the efficacy of Norovirus vaccines and examine the immune response among vaccinated and unvaccinated subjects. The purpose of this study is to generate the infection and illness rate and immune response data necessary for the conduct of future investigation of Norovirus vaccine studies.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–49 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

WCCT Global

Costa Mesa, California, 92626, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • General good health, without significant medical illness, based on medical history, physical examination, vital signs, and clinical laboratories (CBC, chemistry, and urinalysis) as determined by the investigator in consultation with the research monitor and sponsor
  • Available for all planned visits and to spend at least 5 days in confinement
  • Confirmed blood type (A or O)
  • Demonstrated to be H type-1 antigen secretor positive (by saliva test)
  • Body mass index between 17 and 30 at screening
  • Female subjects must have a negative pregnancy test and either use contraceptives or be sterile
  • Available to return for follow-up visits following discharge from the inpatient unit and deliver stool specimens to the investigator promptly

Exclusion criteria

  • Presence of significant medical condition
  • Donation or use of blood or blood products within 4 weeks prior to challenge
  • Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic
  • Abnormal stool pattern
  • Any gastroenteritis within the past 2 weeks
  • Occupational hazards, including having daily contact with children under the age of 5, women known to be pregnant, employment in the food service industry, health care workers, etc.

Treatment and study plan

Norwalk GI.1 Virus

Biological

Norwalk virus causes viral gastroenteritis, which is also known as acute nonbacterial gastroenteritis, food poisoning, food infection, or stomach flu.

Primary outcomes

  1. Frequency of Norovirus Gastroenteritis (NVG)

    Time frame: 7 days post-challenge

    Occurrence of NVG within 7 days post-challenge

Secondary outcomes

  1. Frequency of Serious Adverse Events (SAEs)

    Time frame: 42 ± 3 days post-challenge

    Occurrence of SAEs

Sponsors and collaborators

Lead sponsor

WCCT Global

Industry

Collaborators

  • Vaxart

Registry information

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Oct 26, 2018
Registry last updated
Jan 22, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.